Comparing 3 Schedules of Alimta Plus Gemzar

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine; Pemetrexed

Criteria

Inclusion Criteria:

• Diagnosis of non-small lung cancer

• No prior chemotherapy

• Able to care for self

Exclusion Criteria:

• An ongoing infection

• Pregnancy or breast feeding

• Other serious medical condition

• Cancer that has spread to the brain

• Inability to take folic acid